Erosive esophagitis
Information
- Disease name
- Erosive esophagitis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00206180 | Completed | Phase 4 | NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis | June 2004 | August 2005 |
| NCT00228527 | Completed | Phase 4 | Esomeprazole for Treatment of GERD in Pediatric Patients | October 2004 | October 2005 |
| NCT00586963 | Completed | Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis | January 2008 | December 2008 | |
| NCT00641602 | Completed | Phase 4 | A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis | December 2002 | August 2003 |
| NCT00644735 | Completed | Phase 4 | Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed | December 2002 | January 2004 |
| NCT00693225 | Completed | Phase 4 | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study | January 2008 | December 2010 |
| NCT01306799 | Completed | To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use | January 2010 | April 2015 | |
| NCT01452698 | Completed | Phase 3 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis | August 2012 | |
| NCT01452776 | Completed | Phase 3 | Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis | September 2011 | July 2013 |
| NCT01459367 | Completed | Phase 3 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis | October 2011 | March 2013 |
| NCT01499368 | Completed | Phase 3 | A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients | November 2011 | November 2012 |
| NCT01509261 | Completed | Phase 3 | Efficacy Study of Ilaprazole to Treat Erosive Esophgitis | July 2010 | June 2011 |
| NCT01630746 | Completed | Phase 3 | A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis | July 2012 | September 2013 |
| NCT01642615 | Completed | Phase 2 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents | July 2012 | November 2014 |
| NCT01865825 | Completed | Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? | March 2013 | March 2017 | |
| NCT01874535 | Completed | Phase 4 | Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy | June 2010 | June 2016 |
| NCT02028663 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis | May 2013 | May 2014 |
| NCT02096458 | Completed | Phase 1 | Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets | February 2014 | February 2014 |
| NCT02388724 | Completed | Phase 3 | Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis | March 24, 2015 | July 27, 2017 |
| NCT02388737 | Completed | Phase 3 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis | April 1, 2015 | December 31, 2018 |
| NCT02456935 | Completed | Phase 3 | Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis | May 2015 | September 2016 |
| NCT02679508 | Completed | Phase 4 | Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety | March 20, 2016 | March 5, 2022 |
| NCT02995239 | Completed | Phase 1 | A Study to Compare the Pharmacokinetic Characteristics of CJ-12420 | April 2015 | April 2015 |
| NCT03006874 | Completed | Phase 3 | Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis | May 2, 2016 | March 24, 2017 |
| NCT03736369 | Completed | Phase 3 | Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3) | December 13, 2018 | August 7, 2019 |
| NCT03943992 | Completed | Phase 3 | Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) | January 29, 2019 | July 1, 2020 |
| NCT04124926 | Completed | Phase 3 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis | October 28, 2019 | August 24, 2021 |
| NCT05050188 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 | June 24, 2021 | September 25, 2021 |
| NCT05055128 | Completed | Phase 2 | A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole | August 11, 2021 | September 1, 2022 |
| NCT05890001 | Enrolling by invitation | Phase 3 | A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease | April 5, 2023 | September 30, 2024 |
| NCT04255693 | Recruiting | N/A | Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence | January 31, 2020 | December 31, 2025 |
| NCT02615184 | Recruiting | Phase 2 | A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children | May 23, 2023 | November 17, 2027 |
| NCT05587309 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis | October 30, 2022 | December 29, 2024 |
| NCT06391177 | Recruiting | Phase 1 | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily | June 3, 2024 | August 2024 |
| NCT05267613 | Recruiting | Phase 3 | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | July 1, 2022 | November 6, 2026 |
| NCT05443984 | Recruiting | Phase 3 | JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis | January 17, 2022 | October 31, 2022 |
| NCT02873702 | Terminated | Phase 3 | Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis | December 21, 2016 | November 6, 2017 |
| NCT03228407 | Unknown status | N/A | Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD) | April 28, 2017 | June 2018 |
| NCT04888819 | Unknown status | N/A | Treatment Effect According to Timing of Administration of DWP14012 40 mg | February 1, 2021 | December 31, 2021 |
| NCT04613895 | Unknown status | N/A | Treatment Effect According to Timing of Administration of DWP14012 40 mg | November 17, 2020 | December 30, 2021 |